A Trial Investigating the Dose Linearity and Safety of BC Combo THDB0207 in Subjects With Type 2 Diabetes
Status:
Not yet recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
This is a randomised, double-blind, four-period crossover euglycaemic clamp trial in subjects
with type 2 diabetes.
Each subject will be randomly allocated to one of four treatment sequences. Each sequence
will comprise 3 different single doses of BC Combo THDB0207 (Low dose, Medium dose, and High
dose) and one single dose of Humalog® Mix25.
Subjects will come to the clinical trial centre in a fasted state in the morning of each
dosing day and stay at the clinical trial centre until the 30-hour clamp procedures have been
terminated.